GTN Company
Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years.
At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.
Investors
Connections from
Last Funding Date:
2018-11-01
Total Funding:
2841313
Founded Date:
2017-05-17
Headquarters:
London,England,United Kingdom,Europe
Employee Number:
11-50
Funding Status:
private
Industry:
Quantum Chemistry
Super Industry:
Quantum Science Applications
Funding Stage:
Seed
Funding Total Value:
2100000
Founders:
Noor Shaker,Vid Stojevic